Drug Discovery & ResearchPro
Why the FDA Is Betting on Biology-Driven AI to Fix Drug Development's $2 Billion Failure Problem
Mechanistic AI that explains *why* drugs work—rather than just predicting outcomes—could finally give regulators the transparency needed to accelerate drug development and reduce catastrophic trial failures.
HealthAI Central Editorial Team·June 26, 2026
Opinion & Analysis
What Healthcare AI Can Learn From Vertical AI in Construction
The health AI industry's most durable companies will be those that go deepest in a single clinical domain — not the ones that build the most general-purpose platform. The success of vertical AI in adjacent industries offers a clear template.
HealthAI Central Editorial Team·May 23, 2026
Drug Discovery & Research
Recursion Pharmaceuticals Advances Three AI-Discovered Drug Candidates Into Phase 2 Trials
Recursion Pharmaceuticals has announced that three drug candidates identified through its AI-powered drug discovery platform have advanced into Phase 2 clinical trials, marking a significant milestone for the AI-native pharmaceutical development model.
HealthAI Central Editorial Team·May 3, 2026